Sovereign Investment Advisors LLC purchased a new stake in Elevance Health, Inc. (NYSE:ELV – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund purchased 756 shares of the company’s stock, valued at approximately $279,000.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Greatmark Investment Partners Inc. increased its position in Elevance Health by 24.3% in the 4th quarter. Greatmark Investment Partners Inc. now owns 23,928 shares of the company’s stock valued at $8,827,000 after acquiring an additional 4,678 shares during the period. First Eagle Investment Management LLC increased its position in Elevance Health by 47.6% in the 4th quarter. First Eagle Investment Management LLC now owns 3,225,339 shares of the company’s stock valued at $1,189,828,000 after acquiring an additional 1,039,612 shares during the period. Intact Investment Management Inc. increased its position in Elevance Health by 135.8% during the 4th quarter. Intact Investment Management Inc. now owns 4,150 shares of the company’s stock worth $1,531,000 after purchasing an additional 2,390 shares during the period. Alpine Woods Capital Investors LLC increased its position in Elevance Health by 14.8% during the 4th quarter. Alpine Woods Capital Investors LLC now owns 5,832 shares of the company’s stock worth $2,151,000 after purchasing an additional 750 shares during the period. Finally, King Wealth Management Group increased its position in Elevance Health by 9.0% during the 4th quarter. King Wealth Management Group now owns 3,043 shares of the company’s stock worth $1,123,000 after purchasing an additional 250 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.
Elevance Health Price Performance
Shares of NYSE:ELV opened at $421.72 on Friday. The business’s fifty day moving average price is $395.45 and its two-hundred day moving average price is $429.65. The stock has a market cap of $95.88 billion, a PE ratio of 16.47, a price-to-earnings-growth ratio of 1.18 and a beta of 0.86. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.50 and a current ratio of 1.45. Elevance Health, Inc. has a one year low of $362.21 and a one year high of $567.26.
Elevance Health Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 25th. Stockholders of record on Monday, March 10th will be issued a dividend of $1.71 per share. This is a boost from Elevance Health’s previous quarterly dividend of $1.63. The ex-dividend date of this dividend is Monday, March 10th. This represents a $6.84 annualized dividend and a dividend yield of 1.62%. Elevance Health’s dividend payout ratio (DPR) is 26.71%.
Analysts Set New Price Targets
ELV has been the topic of several recent analyst reports. Barclays boosted their target price on Elevance Health from $501.00 to $512.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Cantor Fitzgerald reiterated an “overweight” rating and set a $485.00 target price on shares of Elevance Health in a research report on Friday, January 24th. Wells Fargo & Company dropped their target price on Elevance Health from $483.00 to $478.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. StockNews.com cut Elevance Health from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Argus reiterated a “hold” rating and set a $405.40 target price on shares of Elevance Health in a research report on Wednesday, January 29th. Four investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Elevance Health has an average rating of “Moderate Buy” and a consensus price target of $517.03.
View Our Latest Analysis on Elevance Health
Insider Transactions at Elevance Health
In other news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the sale, the executive vice president now owns 10,116 shares in the company, valued at $4,008,970.80. This trade represents a 25.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Ronald W. Penczek sold 443 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $415.13, for a total value of $183,902.59. Following the sale, the chief accounting officer now owns 1,847 shares in the company, valued at $766,745.11. This trade represents a 19.34 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.
About Elevance Health
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Recommended Stories
- Five stocks we like better than Elevance Health
- What Are Dividend Champions? How to Invest in the Champions
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- EV Stocks and How to Profit from Them
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.